Trials / Completed
CompletedNCT00248183
A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)
A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 310 (planned)
- Sponsor
- Epix Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in adults with GAD. Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who fulfill the inclusion/exclusion criteria, will be enrolled in this study.
Detailed description
This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in adults with GAD. Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who fulfill the inclusion/exclusion criteria, will be enrolled in this study. This is a randomized, double-blind, placebo controlled, multi-center outpatient study, in adults with GAD. Patients 18-65 years of age, with the diagnosis of GAD according to DSM-IV criteria, who fulfill the inclusion/exclusion criteria, will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRX-00023 |
Timeline
- Start date
- 2005-08-01
- Completion
- 2006-06-01
- First posted
- 2005-11-03
- Last updated
- 2008-04-03
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00248183. Inclusion in this directory is not an endorsement.